SG11201809669RA - Use of glutamate modulating agents with immunotherapies to treat cancer - Google Patents
Use of glutamate modulating agents with immunotherapies to treat cancerInfo
- Publication number
- SG11201809669RA SG11201809669RA SG11201809669RA SG11201809669RA SG11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- bhv
- applicant
- pct
- Prior art date
Links
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title abstract 4
- 229930195712 glutamate Natural products 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004181 riluzole Drugs 0.000 abstract 1
- YBZSGIWIPOUSHY-UHFFFAOYSA-N troriluzole Chemical compound NCC(=O)NCC(N(CC(NC=1SC2=C(N=1)C=CC(=C2)OC(F)(F)F)=O)C)=O YBZSGIWIPOUSHY-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662339433P | 2016-05-20 | 2016-05-20 | |
PCT/US2017/033690 WO2017201502A1 (en) | 2016-05-20 | 2017-05-19 | Use of glutamate modulating agents with immunotherapies to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809669RA true SG11201809669RA (en) | 2018-11-29 |
Family
ID=60326148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809669RA SG11201809669RA (en) | 2016-05-20 | 2017-05-19 | Use of glutamate modulating agents with immunotherapies to treat cancer |
Country Status (25)
Country | Link |
---|---|
US (3) | US20190175731A1 (zh) |
EP (3) | EP3458054B1 (zh) |
JP (4) | JP7224186B2 (zh) |
KR (2) | KR102369735B1 (zh) |
CN (2) | CN109890387B (zh) |
AU (2) | AU2017266951B2 (zh) |
BR (1) | BR112018073781A2 (zh) |
CA (1) | CA3025019A1 (zh) |
CY (1) | CY1124999T1 (zh) |
DK (2) | DK3458053T3 (zh) |
EA (1) | EA201892587A1 (zh) |
ES (2) | ES2905823T3 (zh) |
HR (1) | HRP20220237T1 (zh) |
HU (1) | HUE058184T2 (zh) |
IL (2) | IL292302B2 (zh) |
LT (1) | LT3458053T (zh) |
MX (2) | MX2018013868A (zh) |
PH (1) | PH12018502409A1 (zh) |
PL (1) | PL3458053T3 (zh) |
PT (1) | PT3458053T (zh) |
RS (1) | RS62935B1 (zh) |
SG (1) | SG11201809669RA (zh) |
SI (1) | SI3458053T1 (zh) |
WO (2) | WO2017201502A1 (zh) |
ZA (1) | ZA201807398B (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9725427B2 (en) * | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
AU2016335991A1 (en) | 2015-10-05 | 2018-05-10 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
ES2905823T3 (es) * | 2016-05-20 | 2022-04-12 | Biohaven Therapeutics Ltd | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres |
TWI773694B (zh) | 2016-10-11 | 2022-08-11 | 美商艾吉納斯公司 | 抗lag-3抗體及其使用方法 |
JP6992068B2 (ja) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | 抗ctla-4抗体およびそれらの使用方法 |
BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-h4抗体及びその使用方法 |
WO2019089952A1 (en) * | 2017-11-03 | 2019-05-09 | Calithera Biosciences, Inc. | Conjoint therapy with glutaminase inhibitors |
MX2020008680A (es) * | 2018-02-21 | 2020-09-25 | Ai Therapeutics Inc | Terapia de combinacion con apilimod y agentes glutamatergicos. |
SG11202008105RA (en) | 2018-03-02 | 2020-09-29 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
CA3107215A1 (en) * | 2018-07-22 | 2020-01-30 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
WO2020154579A1 (en) * | 2019-01-24 | 2020-07-30 | University Of Cincinnati | Autologous tumor organoid and immune cell co-cultures and methods of use as predictive models for pancreatic cancer treatment |
CA3141405A1 (en) * | 2019-06-12 | 2020-12-17 | H. Charles Manning | Amino acid transport inhibitors and the uses thereof |
CN110646557A (zh) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途 |
JP7431412B2 (ja) | 2019-12-23 | 2024-02-15 | 三菱マテリアル株式会社 | 被覆電線の分離方法 |
JP2023518218A (ja) * | 2020-03-17 | 2023-04-28 | オハイオ・ステイト・イノベーション・ファウンデーション | 興奮毒性を治療するためのデザイナー細胞外小胞 |
KR102441650B1 (ko) * | 2020-07-31 | 2022-09-08 | 서울대학교병원 | 다중약물 화학요법에 있어서 항암제의 유효 용량 정보의 제공 방법 |
WO2022197767A1 (en) * | 2021-03-17 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for improving survival in lung cancer patients via ketamine oncoprotection |
CN117980002A (zh) * | 2021-07-21 | 2024-05-03 | 维拉克塔附属公司 | 癌症治疗组合 |
WO2023202652A1 (en) * | 2022-04-21 | 2023-10-26 | Jacobio Pharmaceuticals Co., Ltd. | Pharmaceutical combination and use thereof |
CN116492322A (zh) * | 2023-05-10 | 2023-07-28 | 徐州医科大学 | 小分子阻滞剂mem在制备治疗肿瘤药物的应用 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US135A (en) | 1837-03-03 | Jesse j | ||
CA209066A (en) | 1921-03-01 | Tschirner Frederick | Conversion of potassium to soluble state | |
US7812A (en) | 1850-12-03 | Nail-plate feeder and turner | ||
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
AU691195B2 (en) | 1993-07-09 | 1998-05-14 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
WO1998016249A1 (en) | 1996-10-11 | 1998-04-23 | Bristol-Myers Squibb Company | Methods and compositions for immunomodulation |
US6471992B1 (en) | 1997-02-20 | 2002-10-29 | Therics, Inc. | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
CA2286330C (en) | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
WO1999004758A1 (en) | 1997-07-25 | 1999-02-04 | Elan Corporation Plc | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
PL201578B1 (pl) | 1998-11-20 | 2009-04-30 | Skyepharma Canada Inc | Stała terapeutyczna postać dawkowania nierozpuszczalnego lub słabo rozpuszczalnego w wodzie związku |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
EP1191944A2 (en) | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
US6908626B2 (en) | 2001-10-12 | 2005-06-21 | Elan Pharma International Ltd. | Compositions having a combination of immediate release and controlled release characteristics |
US7993674B2 (en) | 2002-02-13 | 2011-08-09 | Weibel Michael K | Drug dose-form and method of manufacture |
DK1487856T3 (da) | 2002-03-04 | 2010-10-18 | Imclone Llc | KDR-specifikke humane antistoffer og deres anvendelse |
US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
CN103467602B (zh) | 2003-07-02 | 2018-04-10 | 依奈特制药公司 | 用于调节nk细胞活性的组合物和方法 |
CN104645327A (zh) | 2003-07-24 | 2015-05-27 | 依奈特制药公司 | 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物 |
US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
EP1791868B1 (en) | 2004-07-01 | 2011-02-23 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
AU2005276132B2 (en) | 2004-08-26 | 2011-09-29 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
RS51362B (en) | 2004-08-26 | 2011-02-28 | Pfizer Inc. | ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
ES2523457T3 (es) | 2004-11-18 | 2014-11-26 | Imclone Llc | Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular |
JP5295568B2 (ja) | 2005-01-06 | 2013-09-18 | ノヴォ ノルディスク アー/エス | Kir結合剤およびその使用方法 |
EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド1(pd−l1)に対するヒトモノクローナル抗体 |
EP1744020A1 (de) | 2005-07-14 | 2007-01-17 | Siemens Aktiengesellschaft | Verfahren zum Starten einer Dampfturbinenanlage |
EP1934260B1 (en) | 2005-10-14 | 2017-05-17 | Innate Pharma | Compositions and methods for treating proliferative disorders |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
PL1959955T3 (pl) | 2005-12-05 | 2011-04-29 | Pfizer Prod Inc | Sposób traktowania nieprawidłowego wzrostu komórek |
CA2632283C (en) | 2005-12-05 | 2011-06-21 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
EP1978939A2 (en) | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
KR101315610B1 (ko) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
US20100189723A1 (en) | 2007-01-11 | 2010-07-29 | Peter Andreas Nicolai Reumert Wagtmann | Anti-kir antibodies, formulations, and uses thereof |
JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用 |
CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
JP5269894B2 (ja) | 2007-06-27 | 2013-08-21 | ハンミ ファーム. シーオー., エルティーディー. | 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置 |
CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
PL2195017T3 (pl) | 2007-10-01 | 2015-03-31 | Bristol Myers Squibb Co | Ludzkie antyciała, które wiążą mezotelinę i ich zastosowania |
ES2572356T3 (es) | 2007-11-09 | 2016-05-31 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos |
JP2011505372A (ja) | 2007-11-30 | 2011-02-24 | ブリストル−マイヤーズ スクウィブ カンパニー | 抗b7h4モノクローナル抗体−薬物コンジュゲートおよび使用方法 |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
US8613937B2 (en) | 2008-10-31 | 2013-12-24 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
KR101958753B1 (ko) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | 인간 cd27에 결합하는 항체 및 이의 용도 |
EP2578585B1 (en) | 2010-05-31 | 2016-07-20 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
AR083957A1 (es) | 2010-11-22 | 2013-04-10 | Innate Pharma Sa | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica |
CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
MX347514B (es) | 2011-05-25 | 2017-04-28 | Innate Pharma Sa | Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios. |
CA2842493A1 (en) | 2011-08-02 | 2013-02-07 | James Gail Christensen | Crizotinib for use in the treatment of cancer |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
JP6541350B2 (ja) | 2011-11-09 | 2019-07-10 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗cxcr4抗体による血液悪性腫瘍の処置 |
US10864271B2 (en) * | 2012-02-15 | 2020-12-15 | Rutgers, The State University Of New Jersey | Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
KR101566538B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Th17 세포 전환용 에피토프 및 이의 용도 |
US10357497B2 (en) * | 2012-06-23 | 2019-07-23 | Biohaven Pharmaceutical Holding Company Limited | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
SG10201702421TA (en) | 2012-10-02 | 2017-05-30 | Bristol Myers Squibb Co | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
AU2014323523B2 (en) | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
MX2016005283A (es) | 2013-10-25 | 2017-02-20 | Pharmacyclics Llc | Tratamiento que utiliza inhibidores de tirosina quinasa de bruton e inmunoterapia. |
IL293212B2 (en) | 2014-05-28 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Anti-GITR antibodies and methods of using them |
US20160009805A1 (en) * | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
US20160073759A1 (en) * | 2014-09-15 | 2016-03-17 | Beauty Solutions Agency Inc. | Nail covering |
US11236139B2 (en) * | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
US10235906B2 (en) * | 2014-11-18 | 2019-03-19 | Maximum Fidelity Surgical Simulations, LLC | Post mortem reconstitution of circulation |
US20160140879A1 (en) * | 2014-11-19 | 2016-05-19 | David Hananel | Anatomically correct movement or deformation of simulated bodily structures |
RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
US11911369B2 (en) * | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
TW201725044A (zh) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | 用於治療癌症之btk抑制劑及查核點抑制劑之組合 |
ES2905823T3 (es) * | 2016-05-20 | 2022-04-12 | Biohaven Therapeutics Ltd | Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres |
-
2017
- 2017-05-19 ES ES17800310T patent/ES2905823T3/es active Active
- 2017-05-19 KR KR1020187036485A patent/KR102369735B1/ko active IP Right Grant
- 2017-05-19 PT PT178003109T patent/PT3458053T/pt unknown
- 2017-05-19 RS RS20220165A patent/RS62935B1/sr unknown
- 2017-05-19 KR KR1020227006275A patent/KR102525527B1/ko active IP Right Grant
- 2017-05-19 AU AU2017266951A patent/AU2017266951B2/en active Active
- 2017-05-19 CN CN201780044939.XA patent/CN109890387B/zh active Active
- 2017-05-19 US US16/302,270 patent/US20190175731A1/en active Pending
- 2017-05-19 MX MX2018013868A patent/MX2018013868A/es unknown
- 2017-05-19 JP JP2018560528A patent/JP7224186B2/ja active Active
- 2017-05-19 EP EP17800311.7A patent/EP3458054B1/en active Active
- 2017-05-19 BR BR112018073781-0A patent/BR112018073781A2/pt active Search and Examination
- 2017-05-19 WO PCT/US2017/033690 patent/WO2017201502A1/en unknown
- 2017-05-19 WO PCT/US2017/033688 patent/WO2017201501A1/en unknown
- 2017-05-19 CN CN202210573206.8A patent/CN115350263A/zh active Pending
- 2017-05-19 EP EP17800310.9A patent/EP3458053B1/en active Active
- 2017-05-19 SI SI201731061T patent/SI3458053T1/sl unknown
- 2017-05-19 DK DK17800310.9T patent/DK3458053T3/da active
- 2017-05-19 LT LTEPPCT/US2017/033688T patent/LT3458053T/lt unknown
- 2017-05-19 IL IL292302A patent/IL292302B2/en unknown
- 2017-05-19 EA EA201892587A patent/EA201892587A1/ru unknown
- 2017-05-19 EP EP21207246.6A patent/EP4019019B1/en active Active
- 2017-05-19 US US16/302,284 patent/US11400155B2/en active Active
- 2017-05-19 SG SG11201809669RA patent/SG11201809669RA/en unknown
- 2017-05-19 ES ES17800311T patent/ES2912131T3/es active Active
- 2017-05-19 HU HUE17800310A patent/HUE058184T2/hu unknown
- 2017-05-19 CA CA3025019A patent/CA3025019A1/en active Pending
- 2017-05-19 DK DK21207246.6T patent/DK4019019T3/da active
- 2017-05-19 JP JP2018560520A patent/JP7169195B2/ja active Active
- 2017-05-19 HR HRP20220237TT patent/HRP20220237T1/hr unknown
- 2017-05-19 PL PL17800310T patent/PL3458053T3/pl unknown
-
2018
- 2018-11-05 ZA ZA2018/07398A patent/ZA201807398B/en unknown
- 2018-11-07 IL IL262849A patent/IL262849B/en unknown
- 2018-11-12 MX MX2022010377A patent/MX2022010377A/es unknown
- 2018-11-15 PH PH12018502409A patent/PH12018502409A1/en unknown
-
2021
- 2021-08-25 AU AU2021221560A patent/AU2021221560B2/en active Active
-
2022
- 2022-02-16 CY CY20221100131T patent/CY1124999T1/el unknown
- 2022-08-01 US US17/878,121 patent/US20230310595A1/en active Pending
- 2022-09-21 JP JP2022150358A patent/JP2022191256A/ja active Pending
- 2022-10-28 JP JP2022173334A patent/JP2023012508A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201901531TA (en) | Regulation of gene expression using engineered nucleases | |
SG11201809554VA (en) | Methods of treating skin cancer by administering a pd-1 inhibitor | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201804765UA (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201901364VA (en) | Engineered target specific nucleases | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201908478SA (en) | Sterilisation method | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11202000145XA (en) | Methods and systems for conditionally regulating gene expression | |
SG11202000055PA (en) | Antibodies that modulate a biological activity expressed by a cell | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 |